Boston Scientific Investors Seek Lead Plaintiff Role in Class Action Lawsuit

Got story updates? Submit your updates here. ›

The law firm of Robbins Geller Rudman & Dowd LLP has announced that purchasers or acquirers of Boston Scientific Corporation (NYSE: BSX) common stock between July 23, 2025 and February 3, 2026 have until May 4, 2026 to seek appointment as lead plaintiff of the Boston Scientific class action lawsuit. The lawsuit alleges that Boston Scientific and certain of its top executives made false and/or misleading statements and/or failed to disclose information about the company's projected revenue outlook and growth potential.

Why it matters

This class action lawsuit represents an opportunity for Boston Scientific investors who suffered substantial losses during the class period to potentially recoup those losses and hold the company accountable for any alleged misconduct. The outcome of the lawsuit could have significant financial implications for both Boston Scientific and its investors.

The details

The Boston Scientific class action lawsuit, captioned Troike v. Boston Scientific Corporation, No. 26-cv-40075 (D. Mass.), alleges that the defendants created a false impression about Boston Scientific's projected revenue outlook and anticipated growth, while minimizing risks from seasonality and macroeconomic fluctuations. The lawsuit further alleges that Boston Scientific's ambition to 'grow our share in the overall EP market' to maintain a growth trajectory at '2x the market' had fallen short due to new competition entrants sapping the company's U.S. Electrophysiology market share and limiting its growth potential.

• The class period for the lawsuit is from July 23, 2025 to February 3, 2026, both dates inclusive.
• The deadline for investors to seek appointment as lead plaintiff is May 4, 2026.

What’s next

The judge in the case will decide on May 4, 2026 whether to allow investors to serve as the lead plaintiff in the class action lawsuit against Boston Scientific.